Liang Xiayuan, Meech Sandra J, Odom Lorrie F, Bitter Mitchell A, Ryder John W, Hunger Stephen P, Lovell Mark A, Meltesen Lynn, Wei Qi, Williams Sara A, Hutchinson Rebecca N, McGavran Loris
Department of Pathology, University of Colorado School of Medicine, Denver, USA.
Am J Clin Pathol. 2004 Apr;121(4):496-506. doi: 10.1309/TLE8-FN6E-YF0N-JGP7.
To evaluate t(2;5) and its variants, we studied 21 pediatric cases of anaplastic lymphoma kinase (ALK)+ anaplastic large cell lymphoma (ALCL) by using immunohistochemical staining, fluorescence in situ hybridization, cytogenetics, and reverse transcriptase-polymerase chain reaction. Results showed 7 (33%) cases with t(2;5), 6 (29%) with variant gene rearrangements, 7 (33%) with uncharacterized rearrangements, and 1 with ALK protein expression but no ALK rearrangement. Among 6 variant gene rearrangements, 1 had TPM4-ALK/t(2;19)(p23;p13) and 2 had inv(2) with the breakpoint proximate to ATIC-ALK and an unknown partner gene separately. The genetic features of the remaining 3 cases were as follows: ins(8;2) with an unknown partner gene; conversion from ALK- at diagnosis to ALK+ at recurrence with unspecified gene rearrangement; complex karyotype without involvement of 2p23, suggesting a cryptic translocation. Concordance between different laboratory results varied from 47% to 81%. These data suggest that ALK variants are not uncommon and underscore the necessity of integrating immunohistochemical, cytogenetic, and molecular genetic approaches to detect, characterize, and confirm t(2;5) and its variant translocations.
为评估t(2;5)及其变异型,我们采用免疫组织化学染色、荧光原位杂交、细胞遗传学和逆转录聚合酶链反应,对21例间变性淋巴瘤激酶(ALK)阳性间变性大细胞淋巴瘤(ALCL)患儿病例进行了研究。结果显示,7例(33%)为t(2;5),6例(29%)为变异基因重排,7例(33%)为未明确的重排,1例有ALK蛋白表达但无ALK重排。在6例变异基因重排中,1例为TPM4-ALK/t(2;19)(p23;p13),2例分别有inv(2),断点分别靠近ATIC-ALK和一个未知伙伴基因。其余3例的基因特征如下:ins(8;2)伴未知伙伴基因;诊断时为ALK阴性复发时转为ALK阳性,基因重排未明确;复杂核型,未累及2p23,提示隐匿性易位。不同实验室结果之间的一致性在47%至81%之间。这些数据表明ALK变异并不罕见,并强调了整合免疫组织化学、细胞遗传学和分子遗传学方法来检测、鉴定和确认t(2;5)及其变异易位的必要性。